Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
12:33pm, Tuesday, 10'th Mar 2026
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
2 Healthcare Stocks That Are Too Cheap to Ignore
12:23pm, Tuesday, 10'th Mar 2026
Pfizer and Novo Nordisk are trading at (more than) reasonable levels given their underlying strengths. Both drugmakers could make pipeline progress that will allow them to improve their financial resu
Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit
10:23am, Tuesday, 10'th Mar 2026
Four names are drawing analyst attention this week, with TD Cowen stepping back from Novo Nordisk A/S (NYSE:NVO), Truist trimming its target on Korn Ferry (NYSE:KFY), Morgan Stanley adjusting expectat
Novo Nordisk receives FDA warning regarding US inspection in 2025
09:44am, Tuesday, 10'th Mar 2026
Novo Nordisk said on Tuesday that it had received a warning letter from the United States Food and Drug Administration (FDA) regarding an inspection at the Danish �
Novo Nordisk: Buying The Dip Before Volume Dominance
09:04am, Tuesday, 10'th Mar 2026
Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a shocking FY2026 guidance cut. Gross margin compressed as D&A and integration c
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Mond
Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen.
05:48am, Tuesday, 10'th Mar 2026
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
Hims & Hers stock: why today's gains are unlikely to be sustainable
01:27pm, Monday, 09'th Mar 2026
Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership with the Danish pharma giant – Novo Nordisk (NYSE: NVO). This meteoric run e
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock
12:00pm, Monday, 09'th Mar 2026
Novo Nordisk is going to drastically reduce the price of its GLP-1 medications next year. The move could give the company's struggling growth rate a big boost.
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why
11:27am, Monday, 09'th Mar 2026
Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
11:05am, Monday, 09'th Mar 2026
Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker's weight-loss medications Wegovy and Ozempic to Hims & Hers
HIMS Skyrockets on Reported Deal with NVO to Sell GLP-1s
11:00am, Monday, 09'th Mar 2026
Multiple reports state that Hims & Hers (HIMS) will partner with Novo Nordisk (NVO) to sell its GLP-1s through the telehealth company's platform. Marley Kayden covers the twists and turns of this tale
Novo Nordisk drops Him & Hers lawsuit
10:38am, Monday, 09'th Mar 2026
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect t
NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?
10:06am, Monday, 09'th Mar 2026
Novo Nordisk erases most gains since Wegovy's 2021 launch as Lilly's drugs outperform its therapies in clinical studies and price cuts loom across its core GLP-1 franchise.
Novo's Quiet Comeback Begins
09:52am, Monday, 09'th Mar 2026
Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability
